LUNG THERAPEUTICS INC
Tyler, TX · Biotech · Acquired
Antifibrotic therapeutic peptides (Caveolin-1 scaffolding domain peptides) formulated as inhaled dry powder and subcutaneous injectable extended-release formulations for treating fibrosis
- Grants
- $1.6M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 26
- 2 granted · 24 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Enhancement of the Beneficial Effects of Mesenchymal Stem Cell (MSC) Treatment by the Caveolin-1 Scaffolding Domain Peptide (CSD) | $224,997 | |
| Federal grant | Department of Health and Human Services · Phase I · Caveolin-1 replacement therapy for the treatment of Idiopathic Pulmonary Fibrosis | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development And Testing Of Subcutaneous Csd Peptide Formulations For Chronic Kidney Disease | $300,228 | |
| Federal grant | Department of Health and Human Services · Phase I · Development And Testing Of Subcutaneous Csd Peptide Formulations For Chronic Kidney Disease | $300,228 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS) | $259,332 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS) | $259,332 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1301 | Windward Bio | — | — |
| 1302 | Azalea Therapeutics | — | — |
| 1303 | Maze Therapeutics | — | — |
| 1304 | LUNG THERAPEUTICS INC | — | — |
| 1305 | Immunomedics | — | — |
| 1306 | INVENIO THERAPEUTICS INC | — | — |
| 1307 | CONFOMETRX, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Modified Peptide Fragments Of CAV-1 Protein And The Use Thereof In The Treatment Of Fibrosisgranted
- Modified Peptide Fragments Of CAV-1 Protein And The Use Thereof In The Treatment Of Fibrosisgranted
- Compositions And Methods For Protecting Type 2 Alveolar Epithelial Cells (AEC2)application
- Modified CAVEOLIN-1 Peptides For The Treatment Of Chronic Kidney Diseaseapplication
- Modified CAVEOLIN-1 Peptide Formulations And Methods Of Manufacturing And Use Thereofapplication
- Epithelial Sodium Channel (enac) Inhibitor Conjugates And Methods For Use Thereofapplication
- Modified CAVEOLIN-1 Peptides For The Treatment Of Post-acute COVID-19application
- Biomarkers For The Treatment Of Interstitial Lung Diseaseapplication
- Modified CAVEOLIN-1 Peptides For The Treatment Of Post-acute COVID-19application
- Biomarkers For The Treatment Of Interstitial Lung Diseaseapplication
- Modified CAVEOLIN-1 Peptides For The Treatment Of Chronic Kidney Diseaseapplication
- Epithelial Sodium Channel (enac) Inhibitor Conjugates And Methods For Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.